ChemoCentryx
ProfileJobs (4)

ChemoCentryx

Suggest Edit
    • Healthcarebiotechdrug developmentpharma

    ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

    Revenue(FY, 2017)
    $82.5 M
    Market capitalization(2018-10-11)
    $504.8 M
    TypePublic
    HQMountain View, US
    Founded1997
    Size (employees)62 (est)
    Websitechemocentryx.com
    ChemoCentryx was founded in 1997 and is headquartered in Mountain View, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at ChemoCentryx

    Thomas J. Schall

    Thomas J. Schall

    President, Chief Executive Officer and Chairman of the Board
    Markus J. Cappel

    Markus J. Cappel

    Chief Business Officer and Treasurer
    Show more

    ChemoCentryx Office Locations

    ChemoCentryx has an office in Mountain View
    Mountain View, US (HQ)
    850 Maude Avenue
    Show all (1)
    Report incorrect company information

    ChemoCentryx Financials and Metrics

    ChemoCentryx Revenue

    ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017
    USD

    Net income (Q2, 2018)

    		(16.3m)

    EBIT (Q2, 2018)

    		(17.3m)

    Market capitalization (11-Oct-2018)

    		504.8m

    Closing stock price (11-Oct-2018)

    		10.0

    Cash (30-Jun-2018)

    		68.8m

    EV

    		450.7m
    ChemoCentryx's current market capitalization is $504.8 m.
    Annual
    USDFY, 2016FY, 2017

    Revenue

    		11.9m82.5m

    General and administrative expense

    		14.7m16.5m

    R&D expense

    		37.9m49.5m

    Operating expense total

    		52.7m66.0m
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

    Revenue

    		2.8m4.3m8.2m9.0m9.5m

    General and administrative expense

    		3.4m3.5m3.7m3.6m3.8m4.1m3.9m3.2m4.6m4.7m9.4m

    R&D expense

    		9.0m7.5m8.4m8.6m7.9m11.2m9.1m8.4m10.0m14.7m32.5m

    Operating expense total

    		12.4m11.1m12.1m12.2m11.7m15.3m12.9m11.6m14.5m15.9m19.4m41.9m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		10.3m16.1m12.8m12.0m40.0m

    Accounts Receivable

    		30.2m51.1m

    Inventories

    		596.0k972.0k757.0k722.0k

    Current Assets

    		134.3m74.3m72.0m148.7m179.8m
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

    Cash

    		13.1m20.9m25.4m11.6m14.6m13.4m21.9m13.9m19.0m18.0m30.6m68.8m

    Accounts Receivable

    		175.0k120.0k30.2m530.0k1.7m164.0k

    Inventories

    		1.3m

    Current Assets

    		100.8m86.1m76.1m71.4m74.2m65.2m127.0m122.7m119.9m122.4m149.8m184.9m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(38.7m)(46.9m)(47.3m)(40.0m)17.9m

    Depreciation and Amortization

    		576.0k543.0k477.0k348.0k418.0k

    Inventories

    Accounts Payable

    		159.0k(161.0k)(73.0k)(4.0k)729.0k
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

    Net Income

    		(12.3m)(10.9m)(12.0m)(12.1m)(11.6m)(15.2m)(10.0m)(7.1m)(6.0m)(6.6m)(9.4m)(16.3m)

    Depreciation and Amortization

    		111.0k227.0k

    Inventories

    		1.3m

    Accounts Payable

    		690.0k1.0m809.0k1.0m615.0k1.3m513.0k840.0k819.0k1.4m(951.0k)(378.0k)
    show all
    USDY, 2018

    EV/EBIT

    		-26 x

    EV/CFO

    		9.1 x

    Financial Leverage

    		7.1 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Kiniksa Pharmaceuticals
    Healthcare - Public
    Biogen
    Healthcare - Public
    MyoKardia
    Healthcare - Public
    Athersys
    Healthcare - Public
    Compare competitors

    ChemoCentryx News and Updates

    September 26, 2018

    ChemoCentryx Announces Proposed Public Offering of Common Stock

    MOUNTAIN VIEW, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to pu…
    May 09, 2018

    ChemoCentryx's (CCXI) CEO Dr. Thomas Schall on Q1 2018 Results - Earnings Call Transcript

    May 07, 2018

    ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech

    March 23, 2018

    ChemoCentryx: Significant Progress In Recent Months

    Report incorrect company information

    ChemoCentryx Company Life and Culture

    Report incorrect company information
    Download PDF